3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Lymphoma, Large B-Cell, Diffuse
80
Leukemia, Myeloid, Acute
74
Multiple Myeloma
70
Breast Neoplasms
69
Lymphoma, Non-Hodgkin
62
Lymphoma
61
Leukemia, Lymphocytic, Chronic, B-Cell
53
Burkitt Lymphoma
53
Recurrence
51
Lymphoma, Follicular
51
Myelodysplastic Syndromes
50
Lymphoma, B-Cell
47
Leukemia
43
Triple Negative Breast Neoplasms
40
Lymphoma, Mantle-Cell
38
Neoplasms
37
Hodgkin Disease
34
Melanoma
33
Lymphoma, B-Cell, Marginal Zone
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Neuroblastoma
28
Ovarian Neoplasms
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
23
Neoplasm Metastasis
22
Leukemia, Biphenotypic, Acute
22
Pancreatic Neoplasms
21
Sarcoma
18
Myeloproliferative Disorders
17
Interventions
liposomal doxorubicin
1
cemiplimab
1
Radiotherapy
1
Paclitaxel
1
Doxorubicin
1
Cyclophosphamide
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Invasive Breast Cancer
×
Cyclophosphamide
×
1 year
×
Clear all
NCT04243616
2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2
Active not recruiting
36 enrolled